Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLEET
NCT07619092Recruiting
- Start
- Jan 2026
- Primary completion
- Aug 2028
- Countries
- 1
01
Overview
Randomised, single-blind trial of flumazenil in major depressive disorder (MDD) and bipolar disorder (BD) (2 arms). Primary endpoint: Screen for Cognitive Impairment in Psychiatry. Started Jan 2026; status: recruiting.
02
Drugs
flumazenil
03
Conditions
major depressive disorder (MDD)bipolar disorder (BD)
Beyond the preview
Go deeper on NCT07619092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07619092.